Pinnacle Associates Ltd. lifted its stake in Evolus, Inc. (NASDAQ:EOLS – Free Report) by 5.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,570,061 shares of the company’s stock after purchasing an additional 82,797 shares during the quarter. Pinnacle Associates Ltd. owned about 2.38% of Evolus worth $12,560,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. GAMMA Investing LLC increased its position in Evolus by 65.6% during the 3rd quarter. GAMMA Investing LLC now owns 3,288 shares of the company’s stock valued at $26,000 after buying an additional 1,303 shares in the last quarter. Legal & General Group Plc bought a new stake in Evolus in the second quarter worth $40,000. Quantbot Technologies LP bought a new stake in Evolus in the second quarter worth $56,000. Sequoia Financial Advisors LLC bought a new stake in Evolus in the second quarter worth $71,000. Finally, WINTON GROUP Ltd purchased a new stake in shares of Evolus in the second quarter worth $77,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.
Evolus Stock Up 0.4%
Shares of NASDAQ EOLS opened at $7.40 on Thursday. Evolus, Inc. has a twelve month low of $3.86 and a twelve month high of $9.31. The firm has a market cap of $488.77 million, a P/E ratio of -14.23 and a beta of 1.33. The company has a 50 day moving average of $8.12 and a 200 day moving average of $6.84.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Evolus in a report on Friday, September 11th. HC Wainwright reiterated a “buy” rating and issued a $13.00 price target on shares of Evolus in a research note on Tuesday, August 25th. Finally, Wall Street Zen raised shares of Evolus from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Evolus currently has an average rating of “Moderate Buy” and an average target price of $14.50.
Check Out Our Latest Stock Analysis on Evolus
Insider Buying and Selling
In other Evolus news, insider David Moatazedi sold 105,108 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total transaction of $950,176.32. Following the sale, the insider directly owned 499,592 shares in the company, valued at approximately $4,516,311.68. This trade represents a 17.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.00% of the company’s stock.
Evolus Profile
Evolus, Inc is a commercial-stage medical aesthetics company focused on developing and marketing products for healthcare providers and consumers. The company’s portfolio is designed to address facial wrinkles, folds and other signs of aging through injectable aesthetic treatments.
Evolus’ flagship product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved in the United States for the temporary improvement of moderate to severe glabellar lines in adults. The company markets Jeuveau in the United States and sells the product internationally under the Nuceiva brand in certain markets.
The company has expanded beyond neuromodulators with its Evolysse collection of injectable hyaluronic acid dermal fillers, which is intended to address facial volume loss and wrinkles.
Featured Stories
- Five stocks we like better than Evolus
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
